I have just come across the Australian Clinical Trial Registration stub for SNT-5506 in myelodysplasia added end of February 2025. First patient anticipated 1/4. 30 patient trial.
Title: Advancing Strategies in Therapy platform trial - Mesenchymal signal targeting in Myelodysplasia as a pathway to transfusion independence and blood count improvement
Background from stub: This is an open label, Phase Ib/II trial with a platform design study for treatment of myelodysplasia. The purpose of this trial is to determine safety, recommended dose, and preliminary efficacy of SNT-5505 in combination with a HMA, ASTX727 (35mg decitabine and 100mg cedazuridine), in patients with transfusion dependent MDS. The initial dose determining part of this domain will be followed by a dose expansion proof of concept cohort. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=387683&isReview=true
SNT Price at posting:
7.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)